Intermolecular, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Quarter Ending December 31, 2018
Revenue for the first nine months of 2018 was $27.3 million, an increase of 3% from $26.7 million in the same period a year ago. Net loss totaled $0.8 million or $0.02 per basic and diluted share, an improvement from a net loss of $10.5 million, or $0.21 per basic and diluted share in the same period a year ago. Non-GAAP net loss for the first nine months of 2018 totaled $0.2 million, or $0.00 per basic and diluted share, an improvement from a non-GAAP net loss of $9.3 million, or $0.19 per basic and diluted share in the same period a year ago. Adjusted EBITDA totaled $3.3 million, an improvement from an adjusted EBITDA loss of $2.8 million in the same period a year ago. Loss from operations was $1.46 million against $10.94 million a year ago. Net cash provided by operating activities was $5.048 million against $0.325 million a year ago. Purchase of property and equipment was $0.620 million against $0.705 million a year ago. Purchase of investments was $21.968 million against $15.505 million a year ago. Non-GAAP operating loss was $0.843 million against $9.722 million a year ago.
For the quarter ending December 31, 2018, the company expects revenue is projected to be in the range of $5.2 million to $5.8 million; Net loss is projected to be between $2.8 million and $3.2 million, or $0.06 per share; Non-GAAP net loss is projected to be between $2.4 million and $2.8 million, or $0.05 per share and $0.06 per share, respectively; and adjusted EBITDA loss is projected to be between $1.8 million and $2.2 million.